CTOs on the Move

Paradigm Diagnostics

www.paradigmdx.com

 
Paradigm is a medical diagnostics company serving physicians and patients worldwide.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Paradigm Diagnostics raised $15M on 05/21/2019

Similar Companies

Octapharma Plasma

Octapharma Plasma is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AgriMetis

AgriMetis discovers, develops, and delivers innovative crop protection products. Our scientific approach is multidisciplinary and integrated which allows AgriMetis to exploit areas of chemical space and production routes that are inaccessible to others. The AgriMetis platform delivers rapid, efficient, and optimal solutions to challenges in crop protection by bringing innovative products and their production processes to the market faster for the $56 billion agricultural chemical industry.

SaskWater

SaskWater is a Moose Jaw, SK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GenBio

GenBio is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Metacrine

We are a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class therapies for patients with liver and gastrointestinal, or GI, diseases. Since our founding in 2014, we have invested in building a foundation of chemistry and biology expertise to drive innovative drug discovery and development. We believe these internal capabilities allow us to gain insights into disease targets and mechanisms and more quickly and purposefully design therapies with characteristics that we view as key to safety and efficacy. With this systematic approach, we have designed novel, proprietary farnesoid X receptor (FXR) clinical product candidates arising from a unique chemical scaffold with the potential to be best-in-class for non-alcoholic steatohepatitis, or NASH, and first- in-class for Inflammatory Bowel Disease, or IBD. In addition to our FXR program, we have continued to invest in drug discovery on other therapeutic targets that have effects on inflammation and/or fibrosis for which we believe we could develop proprietary small molecule therapies.